Today, there are more than 260 medicines in development for neurodegenerative diseases affecting millions of Americans. A new report from PhRMA explores these medicines that target these diseases and conditions.
Get your free copy of the report now.
As America’s aging population expands, so does the increasing need to address and conquer Alzheimer’s disease. It places significant burden on millions of Americans, their caregivers and our health care system as a whole. Despite challenges and setbacks, biopharmaceutical researchers have pushed forward in the search for lifesaving treatments and cures.
However, policies that would limit access to Alzheimer’s disease treatments, like the Centers for Medicare & Medicaid Services (CMS) proposed national coverage determination, are devastating for patients.